Strong Q4 Net Income and EPS
Net income of $108.8M in Q4 2025, or $1.08 per diluted share, up from $71.4M or $0.69 in Q3 2025; increase driven largely by a gain on sale related to Arizona and Kansas divestiture.
Substantial Share Repurchase Activity and Increased Authorization
Repurchased ~3.7M shares through year-end for approximately $118M; repurchased ~2.8M shares (~$90M) in Q4; Board approved incremental $150M authorization raising total to $300M with ~$180M capacity remaining.
Improved Capital Metrics
Common equity Tier 1 ratio increased to 14.38% (up 48 bps QoQ); leverage ratio ~9.61%; tangible book value per share increased 2.9% in Q4 to $22.40.
Balance Sheet Deleveraging and Liquidity Strength
Other borrowed funds reduced from $1.6B at end of 2024 to $0 at end of 2025, strengthening funding flexibility and reducing interest expense on other borrowed funds.
Net Interest Margin Expansion
Fully tax-equivalent NIM of 3.38% in Q4 2025 vs 3.36% in Q3 2025 and 3.20% in Q4 2024; adjusted FTE NIM (ex-purchase accounting accretion) improved to 3.34% (up 4 bps QoQ, up 26 bps YoY).
Credit Quality Trajectory Improving (Q4)
Criticized loans decreased by $112.3M or 9.6% in Q4; non-performing assets decreased by $47.3M or 26% in Q4; funded provision decreased to 1.26% of loans from 1.30% in Q3.
Return of Capital to Shareholders (Dividends)
Declared a quarterly dividend of $0.47 per common share, equating to a 5.7% annualized yield based on average Q4 closing price; returned ~$48M in dividends in Q4.
Footprint Optimization and Operational Restructuring
Completed sale of branches in Arizona and Kansas and announced sale of 11 Nebraska branches; consolidating footprint from 14 states to 10 contiguous states; initiated a flatter banking organization (State Presidents) to speed local decisions and drive organic growth.
Guidance: Expectation of NIM Expansion and Controlled Expenses
Company expects sequential NIM improvement toward >3.50% by year-end 2026, low single-digit deposit growth in 2026, roughly flat to slightly lower total expenses for 2026 (with ~1% higher due to medical normalization included).